Raytheon awarded $71 million in Navy contracts for missile systems
In a recent transaction, Jeffrey M. Rowe, a director at Zomedica Corp. (AMEX:ZOM), acquired a significant amount of the company’s common stock. According to a Form 4 filing with the Securities and Exchange Commission, Rowe purchased shares worth a total of $96,098. The company maintains a strong balance sheet, with InvestingPro data showing more cash than debt and liquid assets exceeding short-term obligations.
The acquisitions took place on March 17, 2025, with Rowe buying a total of 1,714,005 shares. The purchase prices ranged from $0.064 to $0.071 per share. These transactions were conducted through the Jeffrey M. Rowe Living Trust. According to InvestingPro analysis, the stock is currently in oversold territory based on RSI indicators, suggesting potentially attractive entry points for investors.
Following these acquisitions, Rowe now holds a total of 17,140,005 shares in Zomedica, including those held by the Rowe Family GST and an IRA. This move reflects Rowe’s continued investment in the veterinary health company, which is based in Ann Arbor, Michigan. For comprehensive analysis and additional insights about Zomedica, including 13 more exclusive ProTips, visit InvestingPro.
In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported its fourth-quarter 2024 earnings, revealing a revenue of $7.9 million, an 8% increase from the previous year. Despite a net loss of $7.2 million, the company maintained robust gross margins of 70.3% and a strong cash position with $71.4 million in liquidity. Zomedica’s full-year revenue for 2024 reached a record $27.3 million. The company is targeting cash flow breakeven at a $50 million run rate, with plans to continue expanding into the equine market and international territories. Zomedica was recently delisted from the NYSE American Exchange and transitioned to the OTCQB market. The company is focusing on addressing stock valuation issues, as noted by CFO Scott Jordan, who emphasized their commitment to enhancing shareholder value. The veterinary market, which supports Zomedica’s strategy, continues to show steady growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.